Additional Opportunities

MacuSight believes that sirolimus' versatility positions it as a potentially effective treatment for a broad spectrum of ocular diseases and conditions. While the company is presently investigating the compound as a potential therapeutic for the treatment of wet AMD and DME (a manifestation of diabetic retinopathy), as well as the prevention of wet AMD, MacuSight feels that it may also demonstrate efficacy as a treatment for a number of ocular diseases and conditions.

Based on the positive results from its Phase 1 trials of sirolimus, MacuSight is initiating Phase 2 studies in DME and wet AMD, as well as additional ocular diseases and conditions.

MacuSight also plans to investigate sirolimus in combination with other therapies for the treatment of wet AMD. The company will continue to explore these opportunities and advance combination programs as appropriate.

• Disease Targets
• Wet AMD
• Diabetic Macular Edema
• Additional Opportunities

"Sirolimus' versatility positions it as a potentially effective treatment for a broad spectrum of ocular diseases and conditions."